Hercules Capital
Hercules Capital is a capital market company that lends to technology, life sciences, and sustainable technology companies.
Business Model:
Revenue: $294M
Employees: 51-200
Rankings
Detailed Hercules Capital Information
Geographic Data
Address: 400 Hamilton Avenue
City: Palo Alto
State: CA
Zip: 94301
Country: US
Financial Info
Stage:
Raised Last:
$7M
Raised Total:$7M
Social
Twitter
Linkedin
Crunchbase
Metrics
3,157,853Website Global Rank
5,147Website Monthly Traffic
Twitter Followers
Description
Hercules is the largest non-bank lender to venture capital-backed companies at all stages of development in a broadly diversified variety of technology, life sciences, and sustainable and renewable technology industries. With over a decade of experience in venture debt, Hercules is uniquely positioned to quickly create innovative financing solutions that perfectly fit within a company&s;s existing capital structure and map to its business objectives. Recognized as the industry leader, Hercules understands the flexibility these types of companies need and has the experience to work closely with them, even through challenging times, to help them reach critical milestones. Hercules&s; deep sector expertise, geographic presence and its strong capital base have made Hercules the lender of choice for more than 480 innovative companies.
Contact Phone:
+16502893060
Contact Email:
Hercules Capital went public on 5/4/2012 on the NYSE
Listed Exchange:
NYSE
IPO Date:
5/4/2012
Ticker Symbol:
HTGC
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 9/2016 | Druva | Series E | 51M |
| 2/2023 | Skydio | Series E | 0 |
| 5/2007 | Intelliden | Series E | 10M |
| 12/2013 | ViewRay | Venture Round | 0 |
| 12/2021 | NorthSea Therapeutics | Series C | 0 |
| 6/2015 | Proterra | Debt Financing | 25M |
| 6/2009 | Kamada | Venture Round | 20M |
| 10/2020 | Bicycle Therapeutics | Debt Financing | 50M |
| 3/2010 | InfoLogix | Venture Round | 3M |
| 8/2016 | Mattersight | Post-IPO Debt | 30M |
| 6/2013 | Rockwell Medical | Post-IPO Debt | 20M |
| 3/2006 | Compete, Inc. | Venture Round | 4M |
| 6/2005 | Labopharm | Debt Financing | 10M |
| 12/2014 | Dynavax Technologies | Debt Financing | 40M |
| 10/2022 | Replimune Group | Post-IPO Debt | 200M |
| 3/2021 | Humanigen | Post-IPO Debt | 80M |
| 5/2018 | Asensus Surgical | Post-IPO Debt | 40M |
| 4/2007 | Everyday Health Group | Debt Financing | 8M |
| 11/2007 | Zayo | Debt Financing | 85M |
| 7/2018 | Acacia Pharma | Debt Financing | 30M |
| 9/2021 | Corium International | Debt Financing | 235M |
| 6/2017 | Concert Pharmaceuticals | Post-IPO Debt | 30M |
| 9/2021 | 3Gtms | Private Equity Round | 0 |
| 1/2015 | MELA Sciences | Post-IPO Debt | 10M |
| 7/2018 | Merrimack Pharmaceuticals | Post-IPO Debt | 25M |
| 11/2014 | nContact Surgical | Debt Financing | 20M |
| 10/2008 | Blurb | Debt Financing | 2.5M |
| 7/2007 | Purcell Systems | Venture Round | 15M |
| 2/2015 | SparkPost | Debt Financing | 8M |
| 2/2019 | Urovant Sciences | Debt Financing | 100M |
| 4/2016 | FuelCell Energy | Post-IPO Debt | 25M |
| 7/2016 | Aprecia Pharmaceuticals | Debt Financing | 30M |
| 2/2010 | Propel Fuels | Debt Financing | 8M |
| 12/2014 | SOASTA | Debt Financing | 15M |
| 7/2014 | UniQure | Post-IPO Debt | 20M |
| 3/2016 | Mast Therapeutics | Post-IPO Debt | 15M |
| 11/2013 | Celsion | Post-IPO Debt | 20M |
| 3/2010 | Velocity Technology Solutions | Debt Financing | 25M |
| 12/2007 | Shocking Technologies | Debt Financing | 4M |
| 3/2017 | 908 Devices | Debt Financing | - |
| 4/2007 | IKANO Communications | Post-IPO Debt | 22.5M |
| 8/2022 | Provention Bio | Post-IPO Debt | 125M |
| 10/2022 | Bright Machines | Debt Financing | 0 |
| 8/2020 | AVEO Oncology | Post-IPO Debt | 35M |
| 7/2013 | BioAmber | Post-IPO Debt | 25M |
| 11/2012 | TransMedics | Venture Round | 36M |
| 12/2018 | Contentful | Series D | 33.5M |
| 8/2007 | Quartics | Venture Round | 7.5M |
| 1/2006 | Optovia Corporation | Debt Financing | 5M |
| 9/2014 | ChromaDex | Post-IPO Debt | 5M |
| 1/2011 | Anthera Pharmaceuticals | Post-IPO Debt | - |
| 10/2013 | Cleveland BioLabs | Post-IPO Debt | 10M |
| 2/2014 | ADMA Biologics | Post-IPO Debt | 15M |
| 4/2018 | Dashlane | Debt Financing | 10M |
| 10/2006 | IWatt | Venture Round | 7M |
| 4/2019 | Dashlane | Debt Financing | 30M |
| 1/2008 | Kadoink | Debt Financing | 2.5M |
| 6/2015 | Proterra | Series D | 55M |
| 1/2012 | Clustrix | Debt Financing | 4M |
| 9/2007 | Crux Biomedical | Venture Round | 250k |
| 5/2015 | ReachLocal | Post-IPO Debt | 25M |
| 11/2007 | WildTangent | Debt Financing | 20M |
| 8/2017 | BioQ Pharma | Debt Financing | - |
| 6/2010 | BuyerLink | Venture Round | 15M |
| 1/2006 | Simpler Networks | Debt Financing | 10M |
| 2/2017 | Sio Gene Therapies | Post-IPO Debt | 55M |
| 1/2015 | Cerulean Pharma | Post-IPO Debt | 26M |
| 12/2005 | Atrenta | Venture Round | 10M |
| 5/2007 | Neosil | Debt Financing | 10M |
| 7/2017 | Sebacia | Debt Financing | 16M |
| 1/2015 | Bellicum Pharmaceuticals | Post-IPO Debt | - |
| 5/2006 | GameLogic | Debt Financing | 3M |
| 11/2020 | Udacity | Debt Financing | 75M |
| 4/2014 | Alimera Sciences | Post-IPO Debt | 35M |
| 6/2012 | AMSC | Post-IPO Debt | 10M |
| 6/2005 | Sportvision | Debt Financing | 4M |
| 3/2005 | Omrix Biopharmaceuticals | Venture Round | 4.8M |
| 5/2021 | SCYNEXIS | Post-IPO Debt | 60M |
| 6/2013 | Anacor Pharmaceutical | Post-IPO Debt | 45M |
| 5/2015 | Machine Zone | Debt Financing | - |
| 5/2014 | Medrobotics | Series E | 26M |
| 8/2021 | Novelion Therapeutics | Post-IPO Debt | 50M |
| 2/2006 | HighRoads | Debt Financing | 2.5M |
| 4/2007 | NuGEN Technologies | Debt Financing | 3M |
| 8/2010 | Calera | Venture Round | 15M |
| 11/2006 | Elixir Pharmaceuticals | Debt Financing | 15M |
| 8/2006 | Agami System | Debt Financing | 11M |
| 12/2007 | hi5 | Debt Financing | 15M |
| 4/2007 | Rubicon Technology | Post-IPO Debt | 16M |
| 6/2014 | CareCloud Corporation | Debt Financing | 25.5M |
| 12/2013 | CTI BioPharma | Post-IPO Debt | 5M |
| 9/2014 | Edge Therapeutics | Debt Financing | 10M |
| 6/2016 | Plug Power | Post-IPO Debt | 70M |
| 3/2005 | Inxight Software | Debt Financing | 5M |
| 1/2007 | Blurb | Debt Financing | 2.5M |
| 2/2016 | CytRx | Post-IPO Debt | 40M |
| 4/2022 | Viridian Therapeutics | Post-IPO Debt | 0 |
| 6/2022 | Akero Therapeutics | Post-IPO Debt | 0 |
| 4/2014 | JumpStart | Debt Financing | 13M |
| 12/2018 | Nabriva Therapeutics | Post-IPO Debt | 75M |
| 3/2017 | Verastem Oncology | Post-IPO Debt | 25M |
| 3/2013 | Medrobotics | Debt Financing | 10M |
| 3/2018 | Tricida | Debt Financing | 100M |
| 5/2021 | HiberCell | Debt Financing | 30M |
| 6/2022 | Geron | Post-IPO Debt | 0 |
| 4/2018 | RumbleON | Post-IPO Debt | 15M |
| 4/2010 | PolyMedix | Post-IPO Equity | 14M |
| 12/2014 | MELA Sciences | Post-IPO Debt | 20M |
| 5/2009 | E-Band Communications | Series C | - |
| 3/2016 | Quanterix | Series D | 46M |
| 10/2005 | Affinity Express | Venture Round | 3M |
| 3/2019 | Constellation Pharmaceuticals | Post-IPO Debt | 40M |
| 12/2013 | Baxano Surgical | Post-IPO Debt | 15M |
| 4/2007 | Tectura | Debt Financing | 22M |
| 5/2010 | Chroma Therapeutics | Debt Financing | 15M |
| 3/2018 | Metalysis | Venture Round | 16.9M |
| 11/2020 | CloudBolt | Debt Financing | 20M |
| 1/2020 | ChemoCentryx | Post-IPO Debt | 100M |
| 12/2014 | ADMA Biologics | Post-IPO Debt | 5M |
| 6/2017 | Antares Pharma | Post-IPO Debt | 35M |
| 10/2013 | InspireMD | Post-IPO Debt | 10M |
| 7/2022 | Gritstone Bio | Post-IPO Debt | 80M |
| 12/2020 | SingleStore | Series E | 0 |
| 6/2012 | just.me Inc | Debt Financing | 1.5M |
| 5/2005 | WageWorks | Debt Financing | 20M |
| 6/2015 | Zosano Pharma | Post-IPO Debt | 15M |
| 2/2008 | Mode Media | Debt Financing | 20M |
| 10/2005 | AGEIA Technologies | Series C | 27.5M |
| 2/2015 | SparkPost | Series C | 27M |
| 7/2006 | BARRX Medical | Series C | 27.8M |
| 7/2015 | Gynesonics | Venture Round | 43M |
| 9/2021 | Phathom Pharmaceuticals | Post-IPO Debt | 200M |
| 10/2011 | BrightSource Energy | Debt Financing | 35M |
| 6/2020 | G1 Therapeutics | Post-IPO Debt | 100M |
| 7/2006 | BabyUniverse, Inc. | Post-IPO Debt | 5M |
| 12/2013 | AcelRx Pharmaceuticals | Post-IPO Debt | 40M |
| 5/2020 | SingleStore | Debt Financing | 50M |
| 10/2022 | Tricida | Post-IPO Debt | 125M |
| 11/2022 | Kura Oncology | Post-IPO Debt | 125M |
| 7/2012 | Virident Systems | Venture Round | 5.7M |
| 5/2010 | Alexza Pharmaceuticals | Post-IPO Debt | 15M |
| 8/2020 | UNITY Biotechnology | Post-IPO Debt | 80M |
| 10/2017 | Myovant Sciences | Post-IPO Debt | 40M |
| 1/2008 | Rise Broadband | Venture Round | 15M |
| 2/2020 | ZeroFOX | Series D | 74M |
| 7/2016 | Auris Medical | Post-IPO Debt | 12.5M |
| 2/2015 | Agile Therapeutics | Post-IPO Debt | 25M |
| 5/2010 | AVEO Oncology | Post-IPO Equity | 25M |
| 6/2005 | Merrimack Pharmaceuticals | Debt Financing | 9M |
| 10/2021 | Eloxx | Post-IPO Debt | 30M |
| 11/2012 | CapLinked | Series A | 0 |
| 3/2007 | Memory Pharmaceuticals | Post-IPO Debt | 10M |
| 3/2012 | Alphabet Energy | Debt Financing | 2M |
| 1/2006 | Xillix | Debt Financing | 5.5M |
| 8/2012 | Fortress Biotech | Post-IPO Debt | 15M |
| 3/2009 | RazorGator | Debt Financing | 10M |
| 12/2006 | Nexx Systems | Debt Financing | 10M |
| 12/2005 | Cradle Technologies | Series E | 0 |
| 7/2007 | SiCortex | Debt Financing | 10M |
| 8/2005 | Adiana | Series D | 23M |
| 7/2007 | Prism Career Institute | Debt Financing | 3M |
| 3/2019 | Aldeyra Therapeutics | Post-IPO Debt | 60M |
| 8/2006 | NOVASYS MEDICAL | Debt Financing | 8M |
| 5/2006 | OATSystems | Debt Financing | 6M |
| 1/2018 | Intuity Medical | Venture Round | 0 |
| 3/2013 | NeuralStem | Post-IPO Debt | 8M |
| 6/2007 | Panacos Pharmaceuticals | Post-IPO Debt | 20M |
| 8/2022 | Alladapt Immunotherapeutics | Debt Financing | 50M |
| 3/2019 | FuelCell Energy | Post-IPO Debt | - |
| 3/2005 | RazorGator | Series A | 26M |
| 8/2015 | Modumetal | Venture Round | 33.5M |
| 5/2018 | CloudPay | Equity | 25M |
| 2/2015 | Message Systems | Debt Financing | 27M |
| 3/2007 | PSS Systems | Debt Financing | 5M |
| 12/2012 | Comverge | Debt Financing | 34M |
| 4/2006 | Sirtris Pharmaceuticals | Debt Financing | - |
| 6/2014 | Nanotherapeutics | Debt Financing | 30M |
| 11/2006 | Elixir Pharmaceuticals | Series C | 0 |
| 2/2022 | Lucira Health | Post-IPO Debt | 80M |
| 2/2016 | Aria Systems | Series E | 0 |
| 7/2014 | SINTX Technologies | Post-IPO Debt | 0 |
| 11/2014 | Flowonix | Venture Round | 20M |
| 1/2013 | ADMA Biologics | Debt Financing | 6M |
| 6/2016 | Flowonix | Debt Financing | 5M |
| 7/2022 | IVERIC bio | Post-IPO Debt | 250M |
| 4/2016 | ClearObject | Series E | 0 |
| 10/2007 | Diomed Holdings | Debt Financing | 10M |
| 1/2019 | Mesoblast | Post-IPO Debt | 75M |
| 8/2022 | ATAI Life Sciences | Post-IPO Debt | 175M |
| 11/2012 | NuPathe | Post-IPO Debt | 8.5M |
| 1/2023 | AmplifyBio | Debt Financing | 50M |
| 12/2021 | Carwow | Debt Financing | 54.8M |
| 8/2021 | Better Therapeutics | Debt Financing | 50M |
| 2/2015 | Melinta Therapeutics | Post-IPO Debt | 30M |
| 3/2006 | Market Force Information | Debt Financing | 8M |
| 1/2006 | Acceleron Pharma | Debt Financing | 8M |
| 1/2018 | Gynesonics | Private Equity Round | 75M |
| 10/2014 | Gamma Medica | Series B | 0 |
| 3/2006 | RazorGator | Series B | 22.8M |
| 1/2015 | Aspire Bariatrics, Inc. | Debt Financing | 12M |
| 12/2007 | E-Band Communications | Series B | 10M |
| 6/2014 | Celator Pharmaceuticals | Debt Financing | 15M |
| 5/2012 | kaleo | Debt Financing | 15M |
| 3/2007 | Transcept Pharmaceuticals | Series D | 40M |
| 11/2022 | Phathom Pharmaceuticals | Post-IPO Debt | 40M |
| 1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
| 2/2022 | Esme Learning Solutions | Venture Round | 15M |
| 1/2022 | TG Therapeutics | Post-IPO Debt | 70M |
| 2/2019 | TG Therapeutics | Post-IPO Debt | 60M |
| 5/2022 | Madrigal Pharmaceuticals | Post-IPO Debt | 250M |
| 12/2005 | Guava Technologies | Debt Financing | 10M |
| 6/2005 | Sling Media | Debt Financing | 4M |
| 10/2021 | Locus Biosciences | Debt Financing | 25M |
| 11/2022 | Oak Street Health | Post-IPO Debt | 300M |
| 10/2022 | Automation Anywhere | Debt Financing | 200M |
| 10/2006 | Atrenta | Venture Round | 0 |
| 4/2014 | Neos Therapeutics | Debt Financing | 20M |
| 6/2022 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 11/2022 | Locus | Series F | 0 |
| 12/2005 | Cornice | Series C | 97M |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 7/2022 | IVERIC bio | Post-IPO Debt | 0 |
| 7/2022 | Gritstone Bio | Post-IPO Debt | 0 |
| 6/2022 | Geron | Post-IPO Debt | 0 |
| 6/2022 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 6/2022 | Akero Therapeutics | Post-IPO Debt | 0 |
| 5/2022 | Madrigal Pharmaceuticals | Post-IPO Debt | 0 |
| 4/2022 | Viridian Therapeutics | Post-IPO Debt | 0 |
| 2/2022 | Esme Learning Solutions | Venture Round | 0 |
| 2/2022 | Lucira Health | Post-IPO Debt | 0 |
| 1/2022 | TG Therapeutics | Post-IPO Debt | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
